Literature DB >> 23630070

RNA sequencing identifies fusion of the EWSR1 and YY1 genes in mesothelioma with t(14;22)(q32;q12).

Ioannis Panagopoulos1, Jim Thorsen, Ludmila Gorunova, Francesca Micci, Lisbeth Haugom, Ben Davidson, Sverre Heim.   

Abstract

Mesothelioma is a rare but very aggressive tumor derived from mesothelial cells. A number of often complex but nonrandom cytogenetic abnormalities have been found in these tumors, resulting in loss of chromosome bands 14q32 and 22q12 in more than 35% of the cases. In this study, we used RNA sequencing to search for fusion transcripts in a mesothelioma carrying a t(14;22)(q32;q12) as the sole chromosomal aberration and found an EWSR1-YY1 and its reciprocal YY1-EWSR1 fusion transcript. Screening 15 additional cases of mesothelioma from which we had RNA but no cytogenetic information, we identified one more tumor carrying an EWSR1-YY1 fusion gene but not the reciprocal YY1-EWSR1 transcript. RT-polymerase chain reaction and sequencing showed that in both cases exon 8 of EWSR1 (nucleotide 1,139, accession number NM_013986 version 3, former exon 7 in sequence with accession number X66899) was fused to exon 2 of YY1 (nucleotide 1,160, accession number NM_003403 version 3). The EWSR1 breakpoint in exon 8 in the EWSR1-YY1 chimeric transcript is similar to what is found in other fusions involving EWSR1 such as EWSR1-FLI1, EWSR1-DDIT3, and EWSR1-ATF1. The EWSR1-YY1-encoded protein is an abnormal transcription factor with the transactivation domain of EWSR1 and the DNA-binding domain of YY1. This is the first study to detect a specific fusion gene in mesothelioma (the reason how frequent the EWSR1-YY1 fusion is remains uncertain) and also the first time that direct involvement of YY1 in oncogenesis has been demonstrated.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23630070     DOI: 10.1002/gcc.22068

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  16 in total

1.  A Subset of Malignant Mesotheliomas in Young Adults Are Associated With Recurrent EWSR1/FUS-ATF1 Fusions.

Authors:  Patrice Desmeules; Philippe Joubert; Lei Zhang; Hikmat A Al-Ahmadie; Christopher D Fletcher; Efsevia Vakiani; Deborah F Delair; Natasha Rekhtman; Marc Ladanyi; William D Travis; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2017-07       Impact factor: 6.394

2.  Novel insights and recent discoveries on the genetics and pathogenesis of malignant mesothelioma.

Authors:  Yin P Hung; Lucian R Chirieac
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

3.  Molecular characterization of diffuse malignant peritoneal mesothelioma.

Authors:  Yin P Hung; Fei Dong; Matthew Torre; Christopher P Crum; Raphael Bueno; Lucian R Chirieac
Journal:  Mod Pathol       Date:  2020-06-05       Impact factor: 7.842

Review 4.  The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma.

Authors:  Nirosha D Perera; Aaron S Mansfield
Journal:  Curr Oncol Rep       Date:  2022-06-03       Impact factor: 5.075

Review 5.  New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.

Authors:  Anne S Tsao; Harvey I Pass; Andreas Rimner; Aaron S Mansfield
Journal:  J Clin Oncol       Date:  2022-01-05       Impact factor: 44.544

Review 6.  Pleural mesothelioma classification-update and challenges.

Authors:  Sanja Dacic
Journal:  Mod Pathol       Date:  2021-08-31       Impact factor: 7.842

7.  Malignant round cell tumor of bone with EWSR1-NFATC2 gene fusion.

Authors:  Navid Sadri; Julieta Barroeta; Svetlana D Pack; Zied Abdullaev; Bishwanath Chatterjee; Raghunath Puthiyaveettil; John S Brooks; Frederic G Barr; Paul J Zhang
Journal:  Virchows Arch       Date:  2014-07-04       Impact factor: 4.064

8.  Yin Yang 1 promotes mTORC2-mediated AKT phosphorylation.

Authors:  Qiang Zhang; Meimei Wan; Jinming Shi; David A Horita; Lance D Miller; Timothy E Kute; Steven J Kridel; George Kulik; Guangchao Sui
Journal:  J Mol Cell Biol       Date:  2016-01-13       Impact factor: 6.216

9.  Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

Authors:  Julija Hmeljak; Francisco Sanchez-Vega; Katherine A Hoadley; Juliann Shih; Chip Stewart; David Heiman; Patrick Tarpey; Ludmila Danilova; Esther Drill; Ewan A Gibb; Reanne Bowlby; Rupa Kanchi; Hatice U Osmanbeyoglu; Yoshitaka Sekido; Jumpei Takeshita; Yulia Newton; Kiley Graim; Manaswi Gupta; Carl M Gay; Lixia Diao; David L Gibbs; Vesteinn Thorsson; Lisa Iype; Havish Kantheti; David T Severson; Gloria Ravegnini; Patrice Desmeules; Achim A Jungbluth; William D Travis; Sanja Dacic; Lucian R Chirieac; Françoise Galateau-Sallé; Junya Fujimoto; Aliya N Husain; Henrique C Silveira; Valerie W Rusch; Robert C Rintoul; Harvey Pass; Hedy Kindler; Marjorie G Zauderer; David J Kwiatkowski; Raphael Bueno; Anne S Tsao; Jenette Creaney; Tara Lichtenberg; Kristen Leraas; Jay Bowen; Ina Felau; Jean Claude Zenklusen; Rehan Akbani; Andrew D Cherniack; Lauren A Byers; Michael S Noble; Jonathan A Fletcher; A Gordon Robertson; Ronglai Shen; Hiroyuki Aburatani; Bruce W Robinson; Peter Campbell; Marc Ladanyi
Journal:  Cancer Discov       Date:  2018-10-15       Impact factor: 39.397

10.  Pediatric Mesothelioma With ALK Fusions: A Molecular and Pathologic Study of 5 Cases.

Authors:  Pedram Argani; Derrick W Q Lian; Abbas Agaimy; Markus Metzler; Sara E Wobker; Andres Matoso; Jonathan I Epstein; Yun-Shao Sung; Lei Zhang; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2021-05-01       Impact factor: 6.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.